March 30, 2012
Daiichi Sankyo on March 29 announced that it has entered into a research collaboration agreement with California-based bio-venture company NGM Biopharmaceuticals, Inc. to jointly conduct exploratory research of targets related to pancreatic beta-cell regeneration for application in diabetes treatment. Through...read more